5 Key Takeaways

• 1

  The DENALI US subpopulation included 549 patients with primary open-angle glaucoma or ocular hypertension randomized to NCX-470 or latanoprost.

• 2

  NCX-470, or bimatoprost grenod 0.1%, combines prostaglandin-mediated uveoscleral outflow with nitric oxide-mediated trabecular meshwork outflow.

• 3

  NCX-470 met the primary endpoint of noninferiority to latanoprost at every measured time point through month 3.

• 4

  NCX-470 lowered mean intraocular pressure by 8.1 to 10.1 mm Hg, with statistically significant differences at 3 of 6 time points.

• 5

  Cothran reported that NCX-470 was well tolerated, with no serious treatment-related adverse events, and that its safety and efficacy were consistent with MontBlanc phase 3 data.